Sanofi gets USFDA nod for Sarclisa (isatuximab-irfc) for refractory multiple myeloma Medical Dialogues Bureau4 March 2020 6:41 AM GMTSarclisa offers an intravenous (IV) administration and is dosed at 10 mg/kg, in combination with pom-dex, every week for four weeks and then every two...